Previous 10 | Next 10 |
2023-03-31 00:33:34 ET Absci press release ( NASDAQ: ABSI ): Q4 GAAP EPS of -$0.21 beats by $0.04 . Revenue of $1.56M (+7.6% Y/Y) misses by $2.54M . For further details see: Absci GAAP EPS of -$0.21 beats by $0.04, revenue of $1.56M misses by $2.54M
Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- ...
2023-03-24 12:58:39 ET The following slide deck was published by Absci Corporation in conjunction with this event. For further details see: Absci (ABSCI) Investor Presentation - Slideshow
VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Bluep...
VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Absci ma...
Gainers: A-Mark Precious Metals ( AMRK ) +6% . Absci ( ABSI ) +5% . Verve Therapeutics ( VERV ) +5% . Coherus BioSciences ( CHRS ) +5% . SouthState ( SSB ) +4% . Losers: Cytek Biosciences ( CTKB ) -12% . 2U ...
VANCOUVER, Wash. and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion into the European pharmaceutical market with the opening of its Innovation Center, located in Zug, Switzerland. The Zug I...
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 43 rd Annual Cowen Health Care Conference. Absci’s management is scheduled to part...
Absci’s generative AI and wet lab capabilities combined with St. John’s Cancer Institute’s molecular database of cancer patient specimens will accelerate the development of immunotherapies. VANCOUVER, Wash. and NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ...
VANCOUVER, Wash. and NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the expansion of its Scientific Advisory Board with three world-class scientific leaders: Victor Greiff, Ph.D., Timothy Lu, MD, Ph.D., and Hube...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday,...
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stoc...
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 3 rd Annual Life Sciences AI Summit on June 26-27 in New York, ...